ESOU18: The Role of Extended Lymphadenectomy for Bladder Cancer - The American Perspective

Amsterdam, The Netherlands (UroToday.com) Bilateral pelvic lymph node dissection (PLND) is an integral part of radical cystectomy (RC) for bladder cancer (BC). No consensus exists regarding the optimal extent of lymphadenectomy, the number of lymph nodes (LNs) to be retrieved, or the magnitude of the therapeutic benefit given to patients with BC. Most of the literature on the role of PLND in BC is retrospective, nonrandomized and of low quality. There is a lack of prospective randomized trials comparing limited to extended PLND in BC patients.

The American Urologic Association guidelines state that clinicians must perform a bilateral PLND at time of surgery with curative intent. The minimum to be removed are the external, internal, and obturator LN (standard lymphadenectomy).

Disease specific survival is worsened when positive LN are present (figure 1). Mapping studies were performed demonstrating the incidence and location of positive LN (Figure 2), showing that almost all involved LN are included in the boundaries of the true pelvis. It is important to note the limitations of mapping studies, including the fact that the area to which a removed LN is assigned may vary from surgeon to surgeon. Additionally, it remains undetermined how many LNs are left behind and in which anatomic locations. 

It has been shown that limited PLND removes only about 50% of all primary lymphatic landing sites. In order to remove 90%, PLND should be extended to include LNs lateral and medial to the internal iliac vessels, and the common iliac region up to the uretero-iliac crossing. In a meta-analysis of all studies comparing extended and standard PLND, overall odds ratio of 5-year recurrence-free survival rate was 1.63 (95% CI 1.28-2.07, p<0.001), suggesting a significant benefit for the extended PLND [1].

There are currently two phase 3 randomized trials trying to asses which PLND template is the most beneficial. These include the American SWOG 1011 (accrual complete, Pending) examining disease free survival of extended (including common iliac and presacral PLND) vs. standard PLND. This trial included all patients with predominant urothelial carcinoma of the bladder with T2-T4a disease and clinically node negative. The trial was open to a limited set of high volume and highly experienced surgeons and institutions in order to optimize accrual and evaluate the surgical quality monitoring plan. Surgeons included in the trial had to show a history of performing at least 50 cystectomies in the last 3 years and be working in a hospital that performs at least 30 cystectomies each year. Patients were randomized intra-operatively and intra-operative photos were required to assess dissection (figure 3).

The second phase 3 trial is the Association of Urogential Oncology and German Cancer Association (AUO AB25/02 [accrual complete, presented], the LEA trial. This trial examined progression free survival of extended PLND (up to the inferior mesenteric artery) vs. limited PLND. Figure 4 shows comparison of both trials.

Dr. Evans summarized his excellent talk by stating that LN metastasis occur in 25% of patients undergoing RC. Removal of the regional LNs at RC is important to optimize disease specific outcomes in BC patients. The extent of the PLND necessary remains controversial and evidence-based guidelines will require high level data from the prospective randomized trials.

Figure 1: Disease specific survival according to pathological N stage at Radical Cystectomy:
PLND Amer

Figure 2: Mapping study of Pelvic Lymph nodes:
PLNDAmer2

Figure 3: Intraoperative Photo of pelvic Lymph node dissection:
PLNDAmer3

Figure 4:
PLNDAmer4



Speaker: Christopher P. Evans, M.D., FACS, Chair, Department of Urology, Professor Urologic Oncology UC Davis Health, Sacramento California, USA

Written By: Hanan Goldberg, MD, Urologic Oncology Fellow (SUO), University of Toronto, Princess Margaret Cancer Centre @GoldbergHanan at The 15th Meeting of the EAU Section of Oncological Urology ESOU18 - January 26-28, 2018 - Amsterdam, The Netherlands
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe